Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Octreotide × Breast × Clear all

Phase

Phase NA 1 Phase 4 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5 NET 4 Gastrointestinal 3 CNS 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Letrozole 20 Docetaxel 12 Anastrozole 12 exemestane 11 Tamoxifen 11 Capecitabine 10 Paclitaxel 9 Cyclophosphamide 9 Zoledronic Acid 8 Trastuzumab 8 pegfilgrastim 7 Saline Solution 7 Fulvestrant 7 Bupivacaine 7 Sodium Chloride 6 Filgrastim 6 liposomal doxorubicin 5 Ropivacaine 5 Epirubicin 5 Dexmedetomidine 5 Bevacizumab 5 pegylated granulocyte colony-stimulating factor 4 palbociclib 4 abemaciclib 4 Tranexamic Acid 4 Sevoflurane 4 trastuzumab deruxtecan 3 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3 ribociclib 3 pertuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05682209 2023-01-18

The Effect of Octreotide on Wound Drainage After Mastectomy

University College Hospital, Ibadan

Phase 4 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡